PapersFlow Research Brief
Soft tissue tumor case studies
Research Guide
What is Soft tissue tumor case studies?
Soft tissue tumor case studies are detailed clinical, pathological, and genetic analyses of fibrous tumors such as solitary fibrous tumors and desmoid tumors, focusing on recurrent gene fusions like NAB2-STAT6, CTNNB1 mutations, risk assessment, and treatments including surgery, radiation therapy, and targeted therapies like imatinib.
The field encompasses 45,448 papers on clinicopathologic characteristics and treatment strategies for soft tissue tumors. Studies emphasize identification of NAB2-STAT6 gene fusions in solitary fibrous tumors and CTNNB1 mutations in desmoid tumors. Growth rate over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Solitary Fibrous Tumors
Research characterizes clinicopathologic features, NAB2-STAT6 fusions, and STAT6 immunohistochemistry in solitary fibrous tumors across anatomic sites. Studies develop risk stratification models based on patient age, tumor size, and mitoses.
Desmoid Tumors/Aggressive Fibromatosis
Investigations focus on CTNNB1 mutations, beta-catenin activation, and sporadic versus FAP-associated desmoids. Researchers evaluate non-surgical approaches including watchful waiting and medical therapies.
Gene Fusions in Fibrous Tumors
This sub-topic identifies recurrent fusions like NAB2-STAT6, PDGFRB rearrangements, and others defining fibrous tumor entities. Molecular profiling studies establish diagnostic utility via NGS and FISH.
Targeted Therapies for Fibrous Tumors
Clinical trials assess imatinib, sorafenib, and pazopanib efficacy in desmoids and solitary fibrous tumors with kinase fusions. Research correlates responses with mutation status and pathway inhibition.
Risk Assessment in Soft Tissue Fibrous Tumors
Studies develop and validate prognostic models incorporating demographics, histopathology, and genetics for metastasis and recurrence prediction. Validation cohorts refine scoring systems for clinical use.
Why It Matters
Soft tissue tumor case studies guide surgical staging and treatment selection for musculoskeletal sarcomas, as Enneking et al. (1980) established a system that stratifies patients by tumor extent and lymph node involvement, influencing resection decisions in over 2470 cited works. In gastrointestinal stromal tumors (GISTs), Heinrich et al. (2003) linked KIT and PDGFRA mutations to imatinib response, showing primary resistance in 14% of cases with certain mutations, enabling targeted therapy over surgery alone. Demetri et al. (2006) demonstrated sunitinib's efficacy post-imatinib failure, with median progression-free survival of 24.1 weeks versus 6.0 weeks in 312 patients, reducing reliance on radiation or aggressive interventions.
Reading Guide
Where to Start
"Pathology and genetics of tumours of soft tissue and bone" by Fletcher et al. (2002) provides a foundational classification of adipocytic, fibroblastic, and other soft tissue tumors, serving as an accessible entry for understanding case study contexts.
Key Papers Explained
Enneking et al. (1980) "A System for the Surgical Staging of Musculoskeletal Sarcoma" establishes staging fundamentals that Heinrich et al. (2003) "Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor" applies to mutation-driven treatment in GIST cases; Demetri et al. (2006) "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib" builds on this by evaluating second-line therapy efficacy. Fletcher et al. (2002) "Pathology and genetics of tumours of soft tissue and bone" supplies pathological context, while England et al. (1989) "Localized Benign and Malignant Fibrous Tumors of the Pleura" offers histologic criteria linking to these staging and therapeutic advances.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on risk assessment models for desmoid and solitary fibrous tumors using NAB2-STAT6 fusions and CTNNB1 mutations, as noted in the core cluster description. No recent preprints or news from the last 12 months specify new frontiers.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Case report 3 | 1976 | Skeletal Radiology | 4.1K | ✕ |
| 2 | Efficacy and safety of sunitinib in patients with advanced gas... | 2006 | The Lancet | 2.6K | ✕ |
| 3 | A System for the Surgical Staging of Musculoskeletal Sarcoma | 1980 | Clinical Orthopaedics ... | 2.5K | ✕ |
| 4 | Kinase Mutations and Imatinib Response in Patients With Metast... | 2003 | Journal of Clinical On... | 2.3K | ✕ |
| 5 | Pathology and genetics of tumours of soft tissue and bone | 2002 | IARC Press eBooks | 2.1K | ✕ |
| 6 | Gastrointestinal stromal tumors - definition, clinical, histol... | 2001 | Archiv für Pathologisc... | 1.8K | ✓ |
| 7 | Handbuch der Mikroskopischen Anatomie des Menschen | 1958 | — | 1.5K | ✕ |
| 8 | Type 1 Neurofibromatosis Gene: Identification of a Large Trans... | 1990 | Science | 1.5K | ✕ |
| 9 | HEMANGIOPERICYTOMA A VASCULAR TUMOR FEATURING ZIMMERMANNʼS PER... | 1942 | Annals of Surgery | 1.4K | ✕ |
| 10 | Localized Benign and Malignant Fibrous Tumors of the Pleura | 1989 | The American Journal o... | 1.4K | ✕ |
Frequently Asked Questions
What distinguishes benign from malignant localized fibrous tumors of the pleura?
England et al. (1989) reviewed 223 cases, classifying 141 as benign and 82 as malignant based on high cellularity, mitotic activity exceeding four figures per 10 high-power fields, pleomorphism, and hemorrhage. Malignant tumors showed worse outcomes compared to benign ones. These criteria aid pathologists in prognosis and treatment planning.
How do kinase mutations affect imatinib response in GIST patients?
Heinrich et al. (2003) found that most GISTs express mutant KIT or PDGFRA isoforms sensitive to imatinib, but specific mutations like exon 9 KIT confer primary resistance in 14% of cases. Mutation analysis predicts clinical response and guides therapy adjustments. This approach improves outcomes in metastatic settings.
What is the role of sunitinib in advanced GIST after imatinib failure?
Demetri et al. (2006) conducted a randomized trial in 312 patients, showing sunitinib extended median progression-free survival to 24.1 weeks from 6.0 weeks with placebo. The drug was well-tolerated with manageable side effects. It serves as a standard second-line therapy.
What staging system is used for musculoskeletal sarcomas?
Enneking et al. (1980) developed a surgical staging system for musculoskeletal sarcoma based on grade, site, and lymph node/metastasis status, using G (grade), T (tumor site), and R (regional nodes/remote disease). It standardizes preoperative planning and resection margins. The system remains foundational in orthopedic oncology.
What pathological features define gastrointestinal stromal tumors?
Miettinen and Lasota (2001) detailed GIST definition through clinical, histological, immunohistochemical, and molecular genetic features, highlighting KIT and PDGFRA mutations. Differential diagnosis excludes leiomyosarcomas and schwannomas via CD117 staining. These markers confirm diagnosis in over 1839 cited studies.
What genetic basis underlies solitary fibrous tumors?
The cluster identifies NAB2-STAT6 gene fusions as recurrent in solitary fibrous tumors, distinguishing them from histologic mimics. Pathology texts like Fletcher et al. (2002) classify fibroblastic tumors using such fusions. This enables precise diagnosis and targeted risk assessment.
Open Research Questions
- ? How can NAB2-STAT6 fusion variants predict prognosis in solitary fibrous tumors beyond current risk models?
- ? What CTNNB1 mutation subtypes best correlate with desmoid tumor aggressiveness and recurrence post-surgery?
- ? Which patients with advanced GIST develop resistance to sequential imatinib and sunitinib, and why?
- ? How do hemangiopericytoma features overlap with modern solitary fibrous tumor classifications?
- ? What refinements are needed in Enneking staging for contemporary soft tissue sarcoma treatments including targeted therapies?
Recent Trends
The field maintains 45,448 works with no specified 5-year growth rate; foundational papers like Demetri et al. and Heinrich et al. (2003) underscore persistent focus on targeted therapies for GIST within soft tissue tumors.
2006No recent preprints or news coverage alters established trends in NAB2-STAT6 fusions or CTNNB1 mutations.
Research Soft tissue tumor case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Soft tissue tumor case studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers